diabetestalk.net

Diabetes Companies To Invest In

Publicly Traded Diabetes Companies

Publicly Traded Diabetes Companies

List of Publicly Traded Diabetes Companies Listed on U.S. Exchanges The publicly traded companies on this list are biotech, medical device, pharmaceutical companies or other healthcare companies that design, develop, manufacture and/or distribute drugs, equipment, products, systems and/or services relating to diabetes. Examples of the products and services provided by these companies include: Distribution of diabetes products and supplies Glucose monitoring systems Insulin delivery systems Insulin pumps Therapeutic products Most of the large-cap stocks in this category have diabetes products (drugs, therapeutics, devices, etc.) in addition to products in numerous other areas. Resources: Additional publicly traded healthcare companies and healthcare categories can be accessed through the link below: A comparison widget that shows trend, earnings per share (EPS), P/E ratio and beta for each of the companies on this list can be accessed through the link below. Select the company’s link to access charts, news links and company website and social media information. Diabetes Treatment: Large-Cap Stocks Becton, Dickinson and Company (BDX) (Management of diabetes among many devices and diagnostic products) Eli Lilly and Company (LLY) (Animal health, cardiovascular, critical care, diabetes, men’s health, musculoskeletal, neuroscience, oncology) Johnson & Johnson (JNJ) (Pharmaceutical company: diabetes products among many offerings) Medtronic, Inc. (MDT) (Medical device company: diabetes products among many offerings) Novo Nordisk (NVO) (Denmark: diabetes and other serious chronic conditions) Regeneron Pharmaceuticals, Inc. (REGN) (Biopharmaceutical company: antibody technologies; cardiovascular, diabetes, eye diseases, infectious diseases, inflammation, oncology, pain) Sanof Continue reading >>

The Most Innovative Companies In Diabetes

The Most Innovative Companies In Diabetes

Diabetes affects a startling number of people worldwide -- some 415 million in 2015, with 44.3 million of those in North America. About a third of people with diabetes do not know they have it. Last year Quid kicked off a new series focusing on Type 2 diabetes (which accounts for nearly 95% of the world’s cases), including an analysis of 40,000 patient posts from a leading diabetes forum. Still, we wanted to take a closer look at the disease, specifically at innovative companies treating diabetes. First we looked in our proprietary company database of 50,000 startups to see which are receiving the largest VC investments and for what. We identified more than 1,300 companies playing in the diabetes landscape. In the network above, 9.6% of companies focus on research and drug discovery, with a whopping $2.9 billion in investment in this area. And even though it includes fewer companies and makes up a much smaller portion of the network, clinical trial-stage drug manufacturers pulled in the next-highest investment figure, roughly $2 billion in total since 2012. Next, companies in glucose monitoring, diagnostics, and immune-based therapies make up a significant portion of the network and account for a huge chunk of the funds raised. One cluster was particularly interesting in this map: startups in the biotech, small molecules and drug delivery cluster account for just 2.7% of the network but pulled in relatively high investment dollars, topping $955 million. Zooming in, we see that companies in this cluster produce very interesting technologies indeed. Delpor, for example, manufactures a titanium device meant to be implanted into the arm that releases drugs through passive (non-mechanical) diffusion. PhaseBio Pharmaceuticals makes a super-long-acting basal insulin for the Continue reading >>

Private Equity-like Fund Aims To Speed Up Diabetes Research

Private Equity-like Fund Aims To Speed Up Diabetes Research

Dave Johnson says his immediate reaction to his daughter’s diagnosis of Type 1 diabetes at age 4 was typical of any father’s. “It was my baby girl, and my response was I’m going to fix it or pay someone to fix it,” said Mr. Johnson, president and chief executive of the hotel management company Aimbridge Hospitality. “I dove in, spoke to some smart people. But then, I was hit between the eyes that there wasn’t a lot that I was going to be able to do.” That was 22 years ago, and what he did do was volunteer with gusto, organizing fund-raisers in the Dallas area where he lived and working his way up to membership on the executive committee of the international board of the Juvenile Diabetes Research Foundation, the main nonprofit group making grants and evaluating research on the disease. But recently, Mr. Johnson did something that appealed to his business side: He and his wife gave $1 million to a new nonprofit organization, the foundation’s T1D Fund, which invests in companies doing research into Type 1 diabetes. Any financial returns are used to make more investments. “The fund is extremely transparent and crystal clear in its mission,” Mr. Johnson said. “We have a quarterly call and get updates when we’re making investments. It’s run similar to a for-profit.” Structured like a private equity fund, the T1D Fund has a minimum donation of $500,000. The fund, which received $32 million in seed funding from the foundation, has a goal of reaching $80 million. It already has $55 million. Type 1 diabetes is an autoimmune disease that attacks the pancreas and its ability to produce insulin, while Type 2 is a metabolic condition that affects how the body uses glucose. Type 1 also affects fewer people — about 200,000 new cases a year compared with Continue reading >>

Despite Poor Results For Diabetes Drug, Top Pharma Stock Moves Up

Despite Poor Results For Diabetes Drug, Top Pharma Stock Moves Up

Despite disappointing results for its type 2 diabetes drug Budureon, leading pharmaceuticals stock AstraZeneca (AZN) continues to move higher. Last month, rival Novo Nordisk (NVO) jumped on the news. On Thursday, AstraZeneca got an upgrade to its Relative Strength (RS) Rating to 83, clearing the 80 or higher score you look for. Decades of market research shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves. AstraZeneca has moved more than 5% past a 31.98 entry in a first-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average. Earnings-per-share growth decreased in the company's latest report from 29% to 4%. Sales growth showed modest improvement, edging in the right direction from -13% to -12%. AstraZeneca holds the No. 7 rank among its peers in the Medical-Ethical Drugs industry group. Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ) and Grifols (GRFS) are among the top 5 highly rated stocks within the group. RELATED: Continue reading >>

Stock Focus: Diabetes Treatment Companies

Stock Focus: Diabetes Treatment Companies

Ever since Canadian researcher Sir Frederick Banting won the Nobel Prize in 1923 for discovering insulin, diabetes patients have kept the disease in check by taking insulin injections. Frequent injections are not only uncomfortable, but they force patients into a strict daily regimen. Nearly 6% of the U.S. population, or 15.7 million people, suffer from diabetes. Although the percentage of patients with Type 1 diabetes (inherited) is expected to remain constant, more people are expected to be diagnosed with Type 2, which occurs most often in individuals who are overweight or don't get enough exercise. According to the American Diabetes Association, the annual tab for keeping diabetes under control and fighting its debilitating side effects is close to $100 billion. A market so large provides a strong incentive for research on better treatments. Scientists have yet to come up with an effective substitute for insulin, so most of the efforts today focus on developing easier ways to deliver this substance. San Carlos, Calif.-based Inhale Therapeutic Systems is in Phase III clinical trials of its insulin delivery system, which delivers powdered insulin to the patient via an inhaler. The powder, Exubra, was developed by Pfizer and Aventis ; the drug and inhaler will eventually be marketed by Pfizer. Exubera may debut on the market sometime late next year. According to the Value Line Investment Survey, it could generate $2 billion in annual sales by mid-decade. Last year Inhale Therapeutics lost $2.32 per share (before extraordinary items) on sales of $52 million. Thomson Financial/IBES analysts do not expect the company to be profitable until 2003. The table below lists ten companies that market diabetes medications or products, or are working on new therapies. Market values Continue reading >>

Investing For The Global Diabetes Epidemic

Investing For The Global Diabetes Epidemic

This week, fast-food king-pin McDonald’s (NYSE:MCD ) unveiled in Japan its newest creation- Mega Fries. The three-quarters of a pound, 1142 calorie serving of french fries- while potentially delicious- underscores that our new diet of convenience and excess is having some sobering effects on our heaths. As the world moves towards less physical activity and increased consumption of nutritionally deficient foods with higher levels of sugar and saturated fats, obesity rates and its complications will continue to rise, globally. Incidences of one of those complications- diabetes- is rising at an exponential pace. For investors, we can find opportunities in this sobering statistic in the companies that are working towards a cure or treat diabetes. A Growing Global Problem The National Institute of Health estimates that obesity and related complications such as diabetes are our nation's chief health concern. However, while most people tend to think of diabetes and obesity as a developed market problem, the two issues are spreading quite rapidly across the globe. Roughly, four out of five people suffering from diabetes are now located in developing markets. China alone, has 92.3 million diabetic citizens, while India’s diabetic population is over 50 million. Overall, there are nearly 371 million people across the globe that suffer from diabetes and plenty more that are in pre-diabetic stages. However, there ranks are growing quite rapidly. According to a new report from The International Diabetes Federation (IDF), at least one in 10 adults will have diabetes by 2030. Based on factors like aging, demographic changes, diet changes and increasing sedentary lifestyles, the group predicts that an estimated 552 million people could have diabetes in less than two decades' time. O Continue reading >>

Time To Buy Medtronic? Watch Diabetes Segment Transformation

Time To Buy Medtronic? Watch Diabetes Segment Transformation

Summary Medtronic is confident of filling the supply-demand gap in its diabetes franchise by end of FY 2018. The company plans to launch next generation professional CGM device for type 2 diabetes patients in fiscal year 2018. Partnerships with clinics and hospitals for diabetes management and prevention are expected to help Medtronic offer integrated care to patients. The company has also entered intofavorable relationships with major payers in USA. However, investors should be aware ofcertain business risks of the diabetes segment. Medtronic (MDT) is one of the few medical device companies with product portfolio vastly diversified across therapeutic areas and geographies. The inversion deal with Ireland based Covidien has not only helped the company to shift to lower-tax base but has also vastly expanded the company’s geographic and therapeutic footprint. And then the recently concluded divestiture deal with Cardinal Health of non-core and low growth assets for a consideration of $6.1 billion has truly landed this company in an enviable spot. Once Medtronic manages to put to rest the supply constraints it is facing in its diabetes business, I believe that the company can easily reach the 12-month consensus target price for Medtronic, of around $91.11. The diabetes group currently contributes only about 6.3% to Medtronic’s total revenues. However, it is on a cusp of major transformation, one that is capable of lifting or dragging both investor sentiment as well as share price of this diversified medical device player. It should be noted that the lower-than-anticipated revenue performance of the diabetes segment in first quarter of fiscal year 2018 and product recalls of few batches of diabetes pumps has negatively affected the company’s share prices in past few d Continue reading >>

Eli Lilly To Invest $72m In Indianapolis Diabetes Manufacturing

Eli Lilly To Invest $72m In Indianapolis Diabetes Manufacturing

In order to meet growing demand for insulin, pharma giant Eli Lilly said it will invest $72 million to expand insulin manufacturing capabilities at one of its Indianapolis facilities. The company said the multi-million investment will replace an existing insulin vial filling line, which will allow the company to meet increasing demand for insulin products, including Humalog and Humulin. Upgrading its insulin production is part of the company’s plan of investing $850 million across its U.S. manufacturing operations over the course of the year. Initially announced in March, Eli Lilly said the investment would have an intense focus on its diabetes programs. Insulin is a core element of the company’s diabetes business. The company said its Indianapolis facility plays a significant role in its core business. By replacing the existing manufacturing line, Eli Lilly will allow for the installation of a new insulin vial filling line that aligns with modern design expectations and utilizes state-of-the-art technology. David Ricks, chief executive officer of Eli Lilly, said the latest investment reinforces the company’s commitment to the U.S. market and its home of Indianapolis. "Our company is poised for continued growth, and diabetes represents one of our key therapeutic areas. Investments such as this are vital to ensuring we continue meeting the needs of people who use our medicines,” Ricks said in a statement. Maria Crowe, head of Lilly’s global manufacturing operations, said the investments in manufacturing are important in order to keep up with advances in technology and science. She said it’s important that the company’s manufacturing facilities are “recapitalized and modernized regularly” in order to continue providing a steady supply of insulin and othe Continue reading >>

Glooko Raises $7 Million To Enhance Diabetes Management System

Glooko Raises $7 Million To Enhance Diabetes Management System

$7 Million Round from Investors including Samsung Venture Investment Corporation to ramp up growth with health providers and payer groups January 8 , 201 4 – Glooko Inc., makers of a FDA-cleared mobile diabetes management system , announced today it has raised $7 million in a Series A-1 round from several new investors including Samsung Venture Investment Company (SVIC ) and Lifeforce Ventures as well as existing investors including The Social + Capital Partnership , Sundeep Madra and Yogen Dalal. Using this investment, Glooko will focus on enabling predictive diabetes care by delivering patient data and decision-making algorithms to health providers and payer groups. Samsung Venture Investment brings in strategic value given Samsung ’s leadership position in the mobile market globally. “Over the last two years, Glooko has built a diabetes management infrastructure bent on liberating blood glucose data from glucose meters and making it accessible to patients and clinicians,” said Rick Altinger, Glooko’s CEO. “Our next steps are to scale Glooko’s system to global accessibility and to add a layer of analytics and messaging capable of making therapeutic recommendations for diabetes management. The investors who have contributed to this round will help us achieve these goals.” Glooko’s existing investors participated in this financing round with a strong vote of confidence in the company’s vision and direction. “We believe that Glooko can fundamentally disrupt the way diabetes is managed here in the US and other parts of the world,” said Chamath Palihapitiya , Founder & Managing Partner, Social + Capital. Glooko offers an FDA 510(k) cleared diabetes management system focused on making glucose data accessible to both patients and clinicians. The syste Continue reading >>

The 3 Best Diabetes Stocks To Buy In 2018

The 3 Best Diabetes Stocks To Buy In 2018

Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their bloodstream, which can lead to a wide range of health problems. More than 30 million Americans already have diabetes, and another 84 million are at risk of developing the disease. Given these massive numbers, perhaps it isn't shocking to learn that diabetes costs the U.S. healthcare system more than $245 billion annually. A market opportunity that large has attracted the attention of plenty of publicly traded companies: Company Market Cap Products Abbott Laboraties $96 billion Continuous glucose monitor AstraZeneca $84 billion Pharmaceuticals Becton, Dickinson $48 billion Diagnostic and delivery devices Dexcom (NASDAQ:DXCM) $3.8 billion Continuous glucose monitor Eli Lilly $89 billion Insulin and pharmaceuticals Insulet (NASDAQ:PODD) $3.3 billion Insulin pump Johnson & Johnson (NYSE:JNJ) $381 billion Glucose monitor and pharmaceuticals Lexicon Pharmaceuticals $1.1 billion Pharmaceuticals MannKind $364 million Inhaled insulin Medtronic $106 billion Insulin pump and continuous glucose monitor Novo Nordisk (NYSE:NVO) $123 billion Insulin and pharmaceuticals Sanofi $120 billion Insulin and pharmaceuticals Senseonics Holdings $360 million Continous glucose monitor Data source: Yahoo! Finance. Market cap data as of 10/25/17. But which of these diabetes stocks is the best bet for investors heading into 2018? Here are my three favorites. A big competitor throws in the towel Roughly 3 million Americans require artificial insulin to keep their blood sugar levels in a healthy range. While the majority of them rely on pens or needles for insulin delivery, another option is to use an insulin Continue reading >>

Update: Lilly To Invest $85m In Indy As Part Of Diabetes Expansion

Update: Lilly To Invest $85m In Indy As Part Of Diabetes Expansion

Citing a brisk demand for products and a full pipeline of potential new medicines, Eli Lilly and Co. plans to pour $850 million this year into its U.S. research labs, manufacturing plants and other operations, an increase of about $100 million from last year. About $85 million of that will go to expand a manufacturing operation at the Lilly Technology Center southwest of downtown that assembles Trulicity injection pens for diabetes patients, the company said Friday. Lilly CEO Dave Ricks said the total investment will fund projects that are already underway, as well as new projects. “As we have for our entire 140-year history, we continue to see Indiana and the United States as attractive places to research and make the medicines that we sell around the world,” Ricks said. The investment is the latest sign that Lilly, one of the largest employers in Indianapolis with about 11,500 jobs, remains bullish on its ability to roll out new products. In the past two years, the drugmaker has launched medicines for cancer, diabetes, psoriasis and other maladies. Company leaders have announced ambitious goals to launch 20 products in 10 years. The company said the expanded Trulicity plant will be operating using current Lilly manufacturing employees, some of whom might come from elsewhere in the organization. Over the past five years, the company has added about 400 jobs in the city in U.S. diabetes manufacturing. Ricks said Lilly plans to continue investing in its U.S. facilities, especially if the federal government adopts a “more favorable tax environment.” That would include lowering the U.S. corporate tax rate, adding certain innovation incentives, and an “equitable treatment” of foreign earnings, the company said. Lilly had $28 billion of unremitted foreign earning Continue reading >>

5 Pharma Stocks In Focus On World Diabetes Day

5 Pharma Stocks In Focus On World Diabetes Day

Every year, World Diabetes Day is celebrated on Nov 14. This year, the theme is ‘eyes on diabetes’ with a focus on promoting the importance of screening to ensure early diagnosis of type II diabetes and reduce the risk of serious complications. According to information provided by the International Diabetes Foundation (IDF), about 415 million adults were living with diabetes in 2015 with the number expected to increase to around 642 million or one in ten adults by 2040. Moreover, many people with type II diabetes remain unaware of their condition for a long period of time and this may lead to diabetes-related complications by the time the disease is diagnosed. Diabetes can often be the cause of other complications like blindness, cardiovascular disease, lower-limb amputation and kidney failure. It is estimated that about one-third of the 415 million adults living with diabetes will develop some form of diabetic retinopathy while more than 93 million adults currently living with diabetes already have diabetic retinopathy. Meanwhile, as per IDF, global health spending to treat diabetes and manage complications was estimated to be about $673 billion in 2015. Given these statistics, it is not surprising that several healthcare companies devote a significant amount of R&D dollars on developing treatments and devices for diabetes and diabetes management. The diabetes market is highly crowded with companies coming out with innovative treatments promising higher efficacy with lower side effects. Currently available diabetes drugs include different classes of treatments like DPP-4 inhibitors (Januvia, Onglyza, Tradjenta), GLP-1 receptor agonists (Byetta, Victoza) and SGLT-2 (Invokana, Farxiga) apart from metformin and insulin therapy. Stocks to Watch on World Diabetes Day To Continue reading >>

Pharmaceutical Giant Novo Nordisk To Invest £115m In A New Uk Drug Research Centre In Post-brexit 'vote Of Confidence'

Pharmaceutical Giant Novo Nordisk To Invest £115m In A New Uk Drug Research Centre In Post-brexit 'vote Of Confidence'

Danish pharmaceutical giant Novo Nordisk is to invest about £115m over 10 years in a new research centre in Oxford, in a move described by the government as a “vote of confidence” in post-Brexit Britain. About 100 scientists will work at the centre, investigating new approaches to treating type-2 diabetes. David Gauke, chief secretary to the Treasury, said that the move was a “vote of confidence in the UK’s position as a world leader in science and research,” according to the BBC. Novo Nordisk’s executive vice-president and chief science officer Mads Thomsen said Britain’s vote to leave the EU was “unfortunate” but should not affect the collaboration between Oxford and the company. “Obviously we think the Brexit decision was unfortunate. That being said, Oxford University has been around for 800 years so the academic excellence and our company's ability to turn that into medicines hasn't really changed,” Mr Thomsen told the BBC. John Bell, a medicine professor at Oxford, said the new set-up, which will allow for daily interactions between academic and industrial scientists, underlined the importance of sharing research and cutting-edge science across sectors. The UK’s decision to leave the EU has raised concerns in the science sector over a potential gap in funding and sparked concerns amongst drugmakers over future regulation. The European Medicines Agency, a body based in London and responsible for the scientific evaluation and safety monitoring of medicines, warned it is likely to leave after Brexit. Mr Thomsen told the BBC: “We are very happy with the way the European Medicines Agency has worked and everybody is disappointed that it is likely it will have to leave the UK. We hope as many of the current 900 staff as possible will follow it Continue reading >>

27 Best Stocks To Own In 2017

27 Best Stocks To Own In 2017

Amid a dense fog of uncertainty, an aging bull will have to find its footing in 2017. Rarely has the way forward been so obscured by the murky policies of a new political regime, as well as by questions about economic growth, monetary policy and the animal spirits—or lack thereof—of America’s corporate chieftains. With change afoot, along with an essentially sound economy, you’ll do best by favoring stocks over bonds, zeroing in on companies with strong long-term growth trends and rising dividends, and by finding sectors that will prosper with Donald Trump in the White House. Here are 27 stock picks that Kiplinger's investing editors Daren Fonda and Anne Kates Smith, as well as columnist James K. Glassman, see offering promise in the year ahead. Stocks are in alphabetic order. Share prices and other data are as of December 8, 2016. Continue reading >>

Investing In Diabetes Care In Russia

Investing In Diabetes Care In Russia

Watch the video: Together we can change diabetes in Russia Turn on sound Investing in diabetes care in Russia Play video Your browser does not support video playback. To view this content, either upgrade your browser or install Adobe Flash. This player requires a modern web browser or a recent version of Adobe Flash. Install Adobe Flash. Investing in diabetes care in Russia Living with Novo Nordisk 6:00 Cities Changing Diabetes (Danish subtitl... 1:18 Novo Nordisk Way 7:05 Lack of activity is a major risk factor ... 0:42 200 colleagues riding to change diabetes 3:19 10 years with World Diabetes Day 2:16 Share video Next video in 5 Living with Novo Nordisk 6:00 Share "Investing in diabetes care in Russia" Share from current time Share on Facebook Tweet this video Share on LinkedIn More sharing options Pause video Toggle fullscreen 0:00 / 3:22 This case study documents how we in partnership can make a significant contribution to addressing the rising diabetes challenge in Russia by investing in local knowledge and capacity building. It is our proposal on how we can create value together. Diabetes is a serious, chronic health condition that can negatively impact people’s quality of life due to related complications. With 4 million people diagnosed with diabetes in Russia and even more who are undiagnosed, diabetes represents a significant cost to society. Today, diabetes related complications account for a significant portion of the total direct cost of diabetes care in Russia. Russia has made great improvements within healthcare and is now focused on strengthening the pharmaceutical industry. The aim is a significant increase in locally produced pharmaceuticals by 2020. As a leader in diabetes care, we are investing in Russia to ensure availability of high-quality insul Continue reading >>

More in insulin